Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 8;54(3):73-96.
doi: 10.64719/pb.4495.

Intravenous Lidocaine for the Management of Chronic Pain: A Narrative Review of Randomized Clinical Trials

Affiliations
Review

Intravenous Lidocaine for the Management of Chronic Pain: A Narrative Review of Randomized Clinical Trials

Henry Onyeaka et al. Psychopharmacol Bull. .

Abstract

Background: Chronic pain remains a serious health problem with significant impact on morbidity and well-being. Available treatments have only resulted in relatively modest efficacy. Thus, novel therapeutic treatments with different mechanisms have recently generated empirical interest. Lidocaine is postulated to provide anti-inflammatory and anti-nociceptive effect through its action at the N-methyl-D-aspartate (NMDA) and voltage gated calcium receptors. Emerging research indicates that lidocaine could be a reasonable alternative for treating chronic pain.

Objective: Considering the evidence surrounding lidocaine's potential as a therapeutic modality for chronic pain, we conducted a narrative review on the evidence of lidocaine's therapeutic effects in chronic pain.

Methods: A review of the PubMed, and Google scholar databases was undertaken in May 2022 to identify completed studies that investigated the effectiveness of lidocaine in the treatment of chronic pain from database inception to June 2022.

Results: A total of 25 studies were included in the narrative review. Findings on available studies suggest that intravenous infusion of lidocaine is an emerging and promising option that may alleviate pain in some clinical populations. Our narrative synthesis showed that evidence for intravenous lidocaine is currently mixed for a variety of chronic pain syndromes. Findings indicate that evidence for efficacy is limited for: CRPS, and cancer pain. However, there is good evidence supporting the efficacy of intravenous lidocaine as augmentation in chronic post-surgical pain.

Conclusion: Lidocaine may be a promising pharmacologic solution for chronic pain. Future investigation is warranted on elucidating the neurobiological mechanisms of lidocaine in attenuating pain signaling pathways.

Keywords: cancer; chronic post-surgical pain; complex regional pain syndrome; fibromyalgia; lidocaine; pain.

PubMed Disclaimer

References

    1. Zelaya CE, Dalhamer JM, Lucas JW, Connor EM. Chronic pain and high-impact chronic pain among U.S. adults, 2019. 2022 July 6; National Center for Health Statistics; 2020. Accessed. https://www.cdc.gov/nchs/products/databriefs/db390.htm . - PubMed
    1. Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: A systematic review and data synthesis. Pain . 2015;156(4):569–576. doi: 10.1097/01.j.pain.0000460357.01998.f1. doi: - DOI - PubMed
    1. Ahmad F, Cisewski J, Rossen L, Sutton P. Provisional drug overdose death counts. [July 6, 2022];2022 June 15; National Center for Health Statistics. Published. Accessed. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm .
    1. Gordh T, Gordh TE, Lindqvist K, Warner DS. Lidocaine: The origin of a modern local anesthetic. Anesthesiology . 2010;113(6):1433–1437. doi: 10.1097/ALN.0b013e3181fcef48. doi: - DOI - PubMed
    1. Beecham GB, Nessel TA, Goyal A. In: StatPearls. StatPearls Publishing; [July 9, 2022]. Lidocaine. Accessed. http://www.ncbi.nlm.nih.gov/books/NBK539881/ - PubMed

MeSH terms

LinkOut - more resources